Drug Trial Radar · NCT05403749
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Jun 29, 2022
Primary completion
May 13, 2024
Study completion May 13, 2024
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed for multi-center, randomized, double-masked, active-controlled study to evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
dose 1 IBI302Biological
After 4 loading monthly intravitreal injections of dose 1 IBI302,the following IBI302 IVT is given as descript in protocol.
AfliberceptDrug
Three consecutive monthly intravitreal injections of 2.0mg Aflibercept followed by injection every other month
dose 2 IBI302Biological
After 4 loading monthly intravitreal injections of dose 2 IBI302,the following IBI302 IVT is given as descript in protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of BCVA from baselineTime frame: Baseline to week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai First People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.